Although current practice focuses largely on the detection and management of obstructive coronary artery disease (CAD), there is marked heterogeneity in the relationship between CAD and risk for cardiovascular (CV) events. Some patients, despite having obstructive CAD, do not experience cardiovascular events, while others with non-obstructive CAD do. The mechanisms of this high risk coronary plaque (HRCP) development are incompletely understood; application of emerging imaging and molecular technologies holds great promise for simultaneously identifying underlying biological pathways, markers for early noninvasive detection, and novel therapeutic targets for HRCP. Thus, we propose to (1) determine the role of inflammation and other candidate biological pathways in the pathophysiology of HRCP; (2) identify novel biological pathways mediating development of HRCP through machine learning analyses of integrated metabolomic, proteomic and transcriptomic profiling; and (3) determine the incremental prognostic value of these imaging and molecular biomarkers over clinical factors and create an integrated clinico-molecular model of CV event risk prediction. We will accomplish these goals by, for the first time, integrating advanced CTA-based phenotyping of HRCP with molecular profiling and adjudicated CV events, leveraging the robust, existing resources of a large, unique NIH-funded clinical trial of imaging in chest pain patients (PROMISE). This proposal holds great public health significance by augmenting current population- and ischemia- based approaches and more precisely and preemptively identifying those patients at highest risk. Our findings will provide a critical foundation for the development of diagnostics and therapeutics targeted at specific, culprit atherosclerotic phenotypes and molecular pathways.

Public Health Relevance

Patients who develop blockages in the arteries around their hearts (termed coronary artery disease or CAD) often suffer from heart attacks and death due to these blockages. However, some patients who do not have significant CAD also suffer from these events. These patients are felt to have likely had ?vulnerable? or ?high risk? coronary plaque (HRCP). We do not understand well what types of patients develop HRCP or the biology as to why some patients develop HRCP. In this grant, we will analyze data on patients with and without HRCP (identified through a CT scan) who were enrolled in the PROMISE clinical trial to understand which patients develop HRCP and then analyze the blood from these patients. These studies hold potential for helping us understand and identify those patients at greatest risk of HRCP and subsequent heart attacks and death, and to evaluate the biological reasons that these patients develop HRCP.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL146145-02
Application #
9984529
Study Section
Cancer, Heart, and Sleep Epidemiology A Study Section (CHSA)
Program Officer
Reis, Jared P
Project Start
2019-08-01
Project End
2023-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
2
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705